BPC-157 and TB-500 are two of the most studied tissue repair peptides in preclinical research. They are frequently compared — and frequently combined — because they address overlapping but distinct biological pathways. This guide covers what each compound is, how they differ mechanistically, and what the research literature shows about using them separately versus together.
Citation block: BPC-157 and TB-500 are synthetic research peptides studied in preclinical models for tissue repair. BPC-157 is a 15-amino-acid sequence derived from a gastric protein; TB-500 is a synthetic fragment of Thymosin Beta-4. Both are sold for laboratory research only and are not approved for human use.
BPC-157 · 5mg vial
TB-500 · 10mg vial
Quick Comparison
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence derived from a protein found in human gastric juice. It has been studied in preclinical models since the early 1990s and has accumulated one of the largest bodies of preclinical literature of any research peptide.
The primary mechanisms studied include upregulation of growth factors (VEGF, EGF), promotion of angiogenesis (new blood vessel formation), modulation of nitric oxide synthesis, and effects on tendon fibroblast proliferation. BPC-157 is stable in acidic environments, which is unusual for peptides and contributes to its extensive study in gastrointestinal models.
Research has examined BPC-157 in models involving: tendon-to-bone attachment repair, ligament healing, gastric ulcer protection, inflammatory bowel disease, fistula repair, and muscle tissue recovery. See the full BPC-157 research overview for compound-specific documentation.
What Is TB-500?
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein found in most human and animal cells. The TB-500 fragment specifically contains the actin-binding domain of Thymosin Beta-4 — the sequence most associated with the protein’s biological activity in research models.
The primary mechanisms studied include actin sequestration (regulating the ratio of free actin to bound actin in cells), promotion of cell migration (including endothelial cells, keratinocytes, and stem cells), anti-inflammatory signaling, and upregulation of metalloproteinases involved in tissue remodeling. Unlike BPC-157, TB-500 is highly systemic — it promotes cell migration throughout the organism rather than acting primarily at a localized site.
Research has examined TB-500 in models involving: soft tissue wounds, cardiac tissue repair after ischemic events, corneal wound healing, skin wound models, and hair follicle activity. See the full TB-500 research overview for compound-specific documentation.
Key Mechanistic Differences
The most important distinction is that BPC-157 and TB-500 operate through largely non-overlapping pathways, which is why they are studied in combination in many protocols.
BPC-157 primarily works through growth factor signaling and angiogenesis — promoting new blood vessel formation and upregulating growth factors required for tissue regeneration at the site of injury.
TB-500 primarily works through actin dynamics and cell migration. By sequestering G-actin, it promotes cell motility — the migration of repair cells to sites of injury. This systemic mobilization mechanism is distinct from BPC-157’s local growth factor effects.
In combination, the compounds address both the mobilization of repair cells (TB-500) and the local growth factor environment those cells need to function (BPC-157) — which explains why dual-peptide protocols appear frequently in preclinical research literature.
When Researchers Choose Each Compound
BPC-157 research focus
- Tendon and ligament repair models
- GI mucosal protection research
- Bone-to-tendon attachment studies
- Inflammatory bowel disease models
- Localized tissue repair protocols
TB-500 research focus
- Soft tissue wound healing models
- Cardiac tissue repair research
- Systemic cell migration studies
- Corneal and skin wound models
- Protocols requiring systemic distribution
Can BPC-157 and TB-500 Be Used Together?
Yes — dual-peptide protocols combining BPC-157 and TB-500 appear frequently in preclinical research literature. The rationale is mechanistic complementarity: TB-500 promotes the systemic mobilization and migration of repair cells, while BPC-157 creates the local growth factor environment those cells require to complete the repair process.
CoreVionRX offers both compounds individually and as components of the GLOW 70mg blend (GHK-Cu + BPC-157 + TB-500) and KLOW 80mg blend (GHK-Cu + BPC-157 + TB-500 + KPV) for researchers studying multi-compound protocols.
Frequently Asked Questions
Is BPC-157 or TB-500 more studied?
BPC-157 has a larger volume of preclinical literature — over 600 published studies — compared to TB-500, which has approximately 400 studies covering Thymosin Beta-4 and its fragments. BPC-157 has been in active preclinical research since the early 1990s, giving it a longer publication history.
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the naturally occurring 43-amino-acid protein. TB-500 is a synthetic peptide consisting of the actin-binding domain fragment of Thymosin Beta-4 — specifically the sequence most associated with biological activity in research models. TB-500 is used in research as a more accessible analog that retains the key functional characteristics of the full protein.
Why do researchers combine BPC-157 and TB-500?
BPC-157 and TB-500 are combined in research because they operate through complementary rather than overlapping mechanisms. TB-500 promotes the systemic migration of repair cells to injury sites through actin sequestration. BPC-157 promotes the local growth factor environment — particularly VEGF-driven angiogenesis — that migrated repair cells require to function effectively.
Where can I buy BPC-157 and TB-500 for research?
CoreVionRX carries both BPC-157 (5mg) and TB-500 (10mg) individually with independent HPLC purity verification (≥98%) and mass spectrometry identity confirmation. A lot-specific Certificate of Analysis is included with every order. Both compounds are also available as components of the GLOW and KLOW multi-compound blends. All products are for laboratory research use only.
Related Research Guides: How to Read a Peptide COA → · How to Reconstitute Research Peptides → · Research Peptide FAQs →
